
Ellipses Pharma Considers London Listing
Ellipses Pharma is exploring a London listing via a reverse takeover with Wolfram Resources. The British cancer drug developer targets a valuation up to £500 million and aims to complete the deal by early 2027.
Xurve View
Insights:
Xurve View

Ellipses Pharma is exploring a London public listing through a reverse takeover with shell company Wolfram Resources, targeting a valuation of up to £500 million ($660 million). The potential floatation provides a welcome boost to the United Kingdom, which has faced an exodus of firms seeking higher valuations in the United States. Founder and chair Chris Evans said the transaction will allow the cancer drug developer to raise capital from public market investors.





